Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

7.0%

8 terminated/withdrawn out of 114 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

48%

55 trials in Phase 3/4

Results Transparency

50%

48 of 96 completed trials have results

Key Signals

8 recruiting48 with results8 terminated

Enrollment Performance

Analytics

Phase 3

45(40.9%)

Phase 1

27(24.5%)

Phase 2

25(22.7%)

Phase 4

10(9.1%)

Early Phase 1

2(1.8%)

N/A

1(0.9%)

110Total

Phase 3(45)

Phase 1(27)

Phase 2(25)

Phase 4(10)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (114)

Showing 20 of 114 trials

NCT05303064Phase 3Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Role: lead

NCT04987229Phase 3Enrolling By Invitation

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Role: lead

NCT07455383Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Role: lead

NCT07502443Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Role: lead

NCT07540897Phase 3Not Yet Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Role: lead

NCT06767683Phase 2Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Role: lead

NCT06555783Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

Role: lead

NCT06843590Phase 2Recruiting

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Role: lead

NCT05662306Phase 4Terminated

C-Cog in Early Course Schizophrenia Study

Role: collaborator

NCT05028062Phase 4Recruiting

Naltrexone in AUD Reward Drinkers

Role: collaborator

NCT05495984Not ApplicableRecruiting

Neuroplasticity in Maternal Opioid Use Disorder (OUD)

Role: collaborator

NCT01246765Recruiting

National Pregnancy Registry for Psychiatric Medications

Role: collaborator

NCT06358950Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Role: lead

NCT04576507Phase 2Completed

Repeated Cannabis Administration on Experimental Pain and Abuse Liability

Role: collaborator

NCT03201757Phase 3Completed

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Role: lead

NCT04203056Phase 4Terminated

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Role: collaborator

NCT04987658Phase 1Completed

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

Role: lead

NCT01932801Phase 2Completed

Harm Reduction With Pharmacotherapy (HaRP)

Role: collaborator

NCT04928703Early Phase 1Completed

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

Role: collaborator

NCT05547100Phase 1Completed

Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

Role: lead